Boehringer Ingelheim received approval to expand the label claims for its NexGard brands for the treatment of two severe skin diseases in dogs. Both NexGard and NexGard Spectra are now approved for the treatment of the cutaneous diseases demodicosis (caused by the Demodex canis mite) as well as sarcoptic mange (caused by the Sarcoptes scabiei var. canis mite), both in the EU and in Australia.
Ook interessant voor je
![[onderzoek] Marketeers balanceren tussen AI en authentieke merkbeleving](https://www.pharmamarketeer.nl/wp-content/uploads/2025/03/167284-80x60.jpg)
